S&P 500   3,332.74 (-0.56%)
DOW   27,379.52 (-0.74%)
QQQ   276.28 (-0.33%)
AAPL   113.92 (-0.90%)
MSFT   208.10 (-0.64%)
FB   259.63 (+1.09%)
GOOGL   1,461.59 (+0.20%)
AMZN   3,165.00 (-0.29%)
TSLA   422.74 (+0.37%)
NVDA   525.31 (+0.75%)
BABA   277.55 (+0.56%)
CGC   14.56 (+2.46%)
MU   50.70 (+1.97%)
GE   6.08 (-1.94%)
AMD   81.26 (+2.24%)
T   28.17 (-0.74%)
F   6.56 (-1.94%)
ACB   4.94 (+3.35%)
GILD   62.29 (-0.89%)
NFLX   491.19 (+0.11%)
DIS   123.96 (-1.61%)
BA   162.94 (-1.89%)
BAC   23.55 (-2.24%)
S&P 500   3,332.74 (-0.56%)
DOW   27,379.52 (-0.74%)
QQQ   276.28 (-0.33%)
AAPL   113.92 (-0.90%)
MSFT   208.10 (-0.64%)
FB   259.63 (+1.09%)
GOOGL   1,461.59 (+0.20%)
AMZN   3,165.00 (-0.29%)
TSLA   422.74 (+0.37%)
NVDA   525.31 (+0.75%)
BABA   277.55 (+0.56%)
CGC   14.56 (+2.46%)
MU   50.70 (+1.97%)
GE   6.08 (-1.94%)
AMD   81.26 (+2.24%)
T   28.17 (-0.74%)
F   6.56 (-1.94%)
ACB   4.94 (+3.35%)
GILD   62.29 (-0.89%)
NFLX   491.19 (+0.11%)
DIS   123.96 (-1.61%)
BA   162.94 (-1.89%)
BAC   23.55 (-2.24%)
S&P 500   3,332.74 (-0.56%)
DOW   27,379.52 (-0.74%)
QQQ   276.28 (-0.33%)
AAPL   113.92 (-0.90%)
MSFT   208.10 (-0.64%)
FB   259.63 (+1.09%)
GOOGL   1,461.59 (+0.20%)
AMZN   3,165.00 (-0.29%)
TSLA   422.74 (+0.37%)
NVDA   525.31 (+0.75%)
BABA   277.55 (+0.56%)
CGC   14.56 (+2.46%)
MU   50.70 (+1.97%)
GE   6.08 (-1.94%)
AMD   81.26 (+2.24%)
T   28.17 (-0.74%)
F   6.56 (-1.94%)
ACB   4.94 (+3.35%)
GILD   62.29 (-0.89%)
NFLX   491.19 (+0.11%)
DIS   123.96 (-1.61%)
BA   162.94 (-1.89%)
BAC   23.55 (-2.24%)
S&P 500   3,332.74 (-0.56%)
DOW   27,379.52 (-0.74%)
QQQ   276.28 (-0.33%)
AAPL   113.92 (-0.90%)
MSFT   208.10 (-0.64%)
FB   259.63 (+1.09%)
GOOGL   1,461.59 (+0.20%)
AMZN   3,165.00 (-0.29%)
TSLA   422.74 (+0.37%)
NVDA   525.31 (+0.75%)
BABA   277.55 (+0.56%)
CGC   14.56 (+2.46%)
MU   50.70 (+1.97%)
GE   6.08 (-1.94%)
AMD   81.26 (+2.24%)
T   28.17 (-0.74%)
F   6.56 (-1.94%)
ACB   4.94 (+3.35%)
GILD   62.29 (-0.89%)
NFLX   491.19 (+0.11%)
DIS   123.96 (-1.61%)
BA   162.94 (-1.89%)
BAC   23.55 (-2.24%)
Log in
NASDAQ:GWPH

GW Pharmaceuticals PLC- Stock Forecast, Price & News

$98.10
-1.40 (-1.41 %)
(As of 09/29/2020 11:50 AM ET)
Add
Compare
Today's Range
$97.82
Now: $98.10
$100.00
50-Day Range
$98.50
MA: $104.04
$113.95
52-Week Range
$67.98
Now: $98.10
$141.98
Volume3,463 shs
Average Volume456,963 shs
Market Capitalization$3.05 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.78
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of glioblastoma, neonatal hypoxic-ischemic encephalopathy, and schizophrenia. Further, the company has license and development agreements with Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United Kingdom, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Read More
GW Pharmaceuticals PLC- logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.80 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GWPH
CUSIPN/A
Phone44-12-2326-6800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$311.33 million
Cash Flow$0.01 per share
Book Value$23.48 per share

Profitability

Net Income$-9,020,000.00

Miscellaneous

Employees791
Market Cap$3.05 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$98.10
-1.40 (-1.41 %)
(As of 09/29/2020 11:50 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GWPH News and Ratings via Email

Sign-up to receive the latest news and ratings for GWPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











GW Pharmaceuticals PLC- (NASDAQ:GWPH) Frequently Asked Questions

How has GW Pharmaceuticals PLC-'s stock price been impacted by COVID-19?

GW Pharmaceuticals PLC-'s stock was trading at $86.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GWPH shares have increased by 12.9% and is now trading at $98.10.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of GW Pharmaceuticals PLC-?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals PLC- in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for GW Pharmaceuticals PLC-
.

When is GW Pharmaceuticals PLC-'s next earnings date?

GW Pharmaceuticals PLC- is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for GW Pharmaceuticals PLC-
.

How were GW Pharmaceuticals PLC-'s earnings last quarter?

GW Pharmaceuticals PLC- (NASDAQ:GWPH) released its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.02. The biopharmaceutical company had revenue of $121.30 million for the quarter, compared to analyst estimates of $94.57 million. GW Pharmaceuticals PLC- had a negative net margin of 12.56% and a negative return on equity of 7.71%. The firm's quarterly revenue was up 68.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.21 earnings per share.
View GW Pharmaceuticals PLC-'s earnings history
.

What price target have analysts set for GWPH?

13 analysts have issued twelve-month price objectives for GW Pharmaceuticals PLC-'s stock. Their forecasts range from $128.00 to $275.00. On average, they anticipate GW Pharmaceuticals PLC-'s share price to reach $185.08 in the next year. This suggests a possible upside of 88.7% from the stock's current price.
View analysts' price targets for GW Pharmaceuticals PLC-
.

Are investors shorting GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC- saw a increase in short interest in the month of August. As of August 14th, there was short interest totaling 4,490,000 shares, an increase of 14.5% from the July 30th total of 3,920,000 shares. Based on an average daily trading volume, of 339,500 shares, the short-interest ratio is presently 13.2 days. Approximately 17.6% of the shares of the company are short sold.
View GW Pharmaceuticals PLC-'s Short Interest
.

Who are some of GW Pharmaceuticals PLC-'s key competitors?

What other stocks do shareholders of GW Pharmaceuticals PLC- own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals PLC- investors own include Canopy Growth (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Tesla (TSLA), Netflix (NFLX), Intel (INTC), Gilead Sciences (GILD), Aurora Cannabis (ACB) and Advanced Micro Devices (AMD).

Who are GW Pharmaceuticals PLC-'s key executives?

GW Pharmaceuticals PLC-'s management team includes the following people:
  • Dr. Geoffrey W. Guy BSc, LMSSA, Dip Pharm Med, MB BS, MRCS Eng, LRCP, Founder & Chairman (Age 65)
  • Mr. Justin D. Gover, CEO & Exec. Director (Age 48)
  • Mr. Scott M. Giacobello, Chief Financial Officer (Age 49)
  • Mr. Douglas B. Snyder, Chief Legal Officer (Age 55)
  • Mr. Julian S. Gangolli, U.S. Chief Commercial Officer (Age 61)

What is GW Pharmaceuticals PLC-'s stock symbol?

GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH."

How do I buy shares of GW Pharmaceuticals PLC-?

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GW Pharmaceuticals PLC-'s stock price today?

One share of GWPH stock can currently be purchased for approximately $98.10.

How big of a company is GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC- has a market capitalization of $3.05 billion and generates $311.33 million in revenue each year. The biopharmaceutical company earns $-9,020,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis. GW Pharmaceuticals PLC- employs 791 workers across the globe.

What is GW Pharmaceuticals PLC-'s official website?

The official website for GW Pharmaceuticals PLC- is www.gwpharm.com.

How can I contact GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC-'s mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]

This page was last updated on 9/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.